Evidence-Based Summary
No randomized trial comparing retatrutide with semaglutide has been published. In separate placebo-controlled trials in adults with obesity without diabetes, retatrutide groups lost 17.6% to 25.0% of body weight over 80 weeks (TRIUMPH-1; placebo 3.9%), and semaglutide lost 14.9% over 68 weeks (STEP 1; placebo 2.4%). In people with type 2 diabetes, retatrutide groups lost 11.9% to 18.8% over 80 weeks (TRIUMPH-2; placebo 5.1%) and semaglutide 9.6% over 68 weeks (STEP 2; placebo 3.4%). These are figures from different trials with different lengths and participants, so they are not directly comparable. Semaglutide is approved and has shown fewer cardiovascular events than placebo (SELECT); retatrutide has no outcome results yet. TRANSCEND-T2D-2, an open-label trial comparing the two in type 2 diabetes, has not reported.
Quick Comparison: Retatrutide vs Semaglutide
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Class | Investigational triple agonist | Approved GLP-1 receptor agonist |
| Target receptors | GIP, GLP-1 and glucagon receptors | GLP-1 receptor |
| How it is given | Once-weekly injection under the skin in clinical trials only | Once-weekly injection (Ozempic, Wegovy) or daily tablet (Rybelsus, Wegovy tablets), depending on product |
| U.S. regulatory status (October 2026) | Not FDA-approved; investigational. FDA says it cannot be used in compounding | FDA-approved in several products for type 2 diabetes, weight management and defined cardiovascular, kidney and liver indications |
| Strongest human evidence | Phase 3 placebo-controlled trials (TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1) | Phase 3 trials plus cardiovascular (SELECT) and kidney (FLOW) outcome trials |
| Main safety concerns | Gastrointestinal effects; heart-rate rise, low blood pressure and dysesthesia reported; long-term safety unknown | Gastrointestinal effects; label warnings including pancreatitis and gallbladder disease, and a boxed warning based on rodent thyroid C-cell tumors |
| Direct comparison | TRANSCEND-T2D-2 (open-label, type 2 diabetes) active, not recruiting; no results published | Same trial; no results published |
| WADA status (2026 List) | Not named; as a drug with no regulatory approval it may fall under S0 (non-approved substances) | Not named on the 2026 Prohibited List |
One Receptor vs Three
Semaglutide copies the action of GLP-1, a gut hormone that boosts insulin after meals and reduces appetite. Retatrutide adds GIP (another gut hormone) and glucagon (a pancreatic hormone that also raises energy use). More targets does not automatically mean a better or safer medicine.
Retatrutide
Primary Target: GIP, GLP-1 and glucagon receptors
Affinity Profile: Triple agonist; in lab assays, strongest at the GIP receptor
In obese mice, glucagon-receptor activity added higher energy expenditure to reduced food intake. These are animal findings; human trials measure the drug as a whole.
Semaglutide
Primary Targets: GLP-1 receptor
Affinity Profile: Selective GLP-1 receptor agonist
Supports glucose-dependent insulin release, lowers glucagon and reduces food intake. Its long action allows weekly injection or daily oral dosing in specific products.
FDA Status: Approved Medicine vs Investigational Drug
United States status checked 10–11 October 2026. Approved uses belong to each named product and formulation.
Retatrutide Status & Formulations
Not FDA-approved. No retatrutide product appears in Drugs@FDA. FDA states that retatrutide is not a component of any FDA-approved drug, has not been found safe and effective for any condition and cannot be used in compounding.
Semaglutide Status & Formulations
Ozempic injection covers type 2 diabetes and specified cardiovascular and kidney risk indications. Rybelsus and Ozempic tablets have their own diabetes and cardiovascular indications. Wegovy injection and tablets cover defined weight and cardiovascular indications; pediatric and MASH indications differ by formulation. Sharing an ingredient does not make labels interchangeable.
Critical Regulatory Distinction
Phase 3 results are not an approval. Compounded semaglutide is not an FDA-approved equivalent of the branded products, and online retatrutide is an unapproved drug.
TRIUMPH vs STEP: Separate Trial Programs
Most of the evidence for each drug comes from placebo-controlled trials. Numbers from different trials are not directly comparable because populations, trial length and analysis methods differ.
Retatrutide: Clinical Evidence Overview
TRIUMPH-1 (2,339 adults with obesity without diabetes, 80 weeks): weight change −17.6%, −23.7% and −25.0% across three retatrutide groups vs −3.9% with placebo. TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes, 80 weeks): −11.9% to −18.8% vs −5.1%. In a 48-week phase 2 trial, weight change ranged from −8.7% to −24.2% vs −2.1%. All funded by Eli Lilly. No outcome trial has reported.
Semaglutide: Clinical Evidence Overview
STEP 1 (1,961 adults with overweight or obesity without diabetes, 68 weeks): −14.9% vs −2.4% with placebo. STEP 2 (1,210 adults with overweight or obesity and type 2 diabetes, 68 weeks): −9.6% vs −3.4%. SELECT (17,604 adults with cardiovascular disease and overweight or obesity, no diabetes): major cardiovascular events 6.5% vs 8.0% with placebo (HR 0.80). All funded by Novo Nordisk.
Curated Clinical Evidence Table
A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.
| Study & Citation | Population | Comparison & Dosing | Duration | Main Endpoint | Key Finding | Methodological Limitations |
|---|---|---|---|---|---|---|
| TRIUMPH-1 (Jastreboff et al., NEJM 2026) | 2,339 adults with obesity, without diabetes | Retatrutide (three dose groups) vs placebo | 80 weeks | Percent change in body weight | −17.6% to −25.0% vs −3.9% with placebo. | Placebo-controlled; industry funded. |
| TRIUMPH-2 (Bellido et al., Lancet 2026) | 1,152 adults with obesity and type 2 diabetes | Retatrutide (three dose groups) vs placebo | 80 weeks | Percent change in body weight | −11.9% to −18.8% vs −5.1% with placebo. | Hypotension and dysesthesia more common than placebo. |
| STEP 1 (Wilding et al., NEJM 2021) | 1,961 adults with overweight or obesity, without diabetes | Weekly injectable semaglutide vs placebo, both with lifestyle intervention | 68 weeks | Percent change in body weight | −14.9% vs −2.4% with placebo. | Shorter than TRIUMPH-1; not directly comparable. |
| STEP 2 (Davies et al., Lancet 2021) | 1,210 adults with overweight or obesity and type 2 diabetes | Weekly injectable semaglutide vs placebo | 68 weeks | Percent change in body weight | −9.6% vs −3.4% with placebo. | Different trial from TRIUMPH-2; not directly comparable. |
| SELECT (Lincoff et al., NEJM 2023) | 17,604 adults with cardiovascular disease and overweight or obesity, no diabetes | Weekly injectable semaglutide vs placebo | Mean 39.8 months | Cardiovascular death, heart attack or stroke | 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90). | No equivalent retatrutide result exists yet. |
| TRANSCEND-T2D-2 (NCT06260722, registry record) | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor; estimated 1,250 | Retatrutide vs semaglutide, open-label | Not yet reported | Efficacy and safety (registry) | Active, not recruiting; no results posted or published as of 11 October 2026. | Open-label design; results pending. |
Adverse Effects: Established Label vs Trial-Only Data
Semaglutide's safety profile is described in FDA labels backed by large trials and years of use. Retatrutide's comes only from clinical trials.
Semaglutide only: Boxed Warning for thyroid C-cell tumors
Semaglutide labels carry a boxed warning because thyroid C-cell tumors occurred in rodents; whether this happens in humans is unknown. Retatrutide has no FDA label, so no labelled warnings exist for it; that is not evidence that it is safer.
| Safety Consideration | Retatrutide | Semaglutide |
|---|---|---|
| Most common adverse effects | Gastrointestinal: diarrhoea, nausea, vomiting | Gastrointestinal: nausea, diarrhoea, vomiting, constipation |
| Signals to watch | Dose-dependent heart-rate increase (phase 2); hypotension and dysesthesia more common than placebo (TRIUMPH-2) | Label warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury |
| Stopping because of gastrointestinal or other adverse events | TRIUMPH-2: up to 12% in one retatrutide group vs 5% with placebo (adverse events or death) | STEP 1: 4.5% stopped because of gastrointestinal events vs 0.8% with placebo |
| Long-term outcome data | None yet; TRIUMPH-Outcomes ongoing | SELECT and FLOW outcome trials completed |
What Retatrutide and Semaglutide Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Shared GLP-1 receptor action
Both activate the GLP-1 receptor, which reduces appetite and supports insulin release.
Once-weekly injection
Both are tested or used as weekly injections; semaglutide also has oral products.
Gastrointestinal side effects
Nausea, diarrhoea and vomiting are the most common side effects for both.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Number of receptor targets
Retatrutide also targets GIP and glucagon receptors; semaglutide targets GLP-1 only.
Regulatory status
Semaglutide is FDA-approved in multiple products; retatrutide is not approved for any use.
Outcome evidence
Semaglutide reduced cardiovascular events versus placebo in SELECT; retatrutide has no outcome results.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Retatrutide causes twice the weight loss of semaglutide
Not supportedRetatrutide is not FDA-approved; semaglutide's approved uses are product-specific.
This comes from setting figures from separate trials side by side. Different trials are not directly comparable, and no head-to-head result has been published.
Switching from semaglutide to online retatrutide is a safe upgrade
Not supportedFDA has warned companies selling unapproved retatrutide as a research product.
Online retatrutide is unapproved, its contents are unverified, and switching between these drugs has not been studied in published trials.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Weight reduction in adults with obesity
Retatrutide: positive phase 3 trials, not approved. Semaglutide: multiple phase 3 trials and approved labels.
Glucose control in type 2 diabetes
Retatrutide improved glucose in phase 3 trials; semaglutide is approved for type 2 diabetes.
Cardiovascular outcomes
SELECT showed fewer major cardiovascular events with semaglutide than placebo; no retatrutide outcome data yet.
Retatrutide vs semaglutide directly
No published head-to-head trial; TRANSCEND-T2D-2 is pending.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Direct comparison
TRANSCEND-T2D-2 compares retatrutide with semaglutide in type 2 diabetes; no obesity head-to-head trial has reported.
Outcomes and long-term safety
Retatrutide's cardiovascular and kidney outcome trial is ongoing, and its heart-rate and dysesthesia signals need longer study.
Funding
Retatrutide trials were funded by Eli Lilly and semaglutide trials by Novo Nordisk; independent comparisons are lacking.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Phase 3 randomized controlled trial
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityTRIUMPH-1; funded by Eli Lilly.
-
Phase 3 randomized controlled trial
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
-
Phase 2 randomized controlled trial
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
-
Phase 3 randomized controlled trial
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
-
Discovery and phase 1 study
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
-
Phase 3 randomized controlled trial
Once-Weekly Semaglutide in Adults with Overweight or ObesitySTEP 1; funded by Novo Nordisk.
-
Phase 3 randomized controlled trial
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialArticle title reproduced as published; it is not dosing guidance.
-
Cardiovascular outcomes trial
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
-
Kidney outcomes trial
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
-
Registry record
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Phase 3, open-label, active, not recruiting; estimated 1,250 participants; sponsor Eli Lilly. Checked 11 October 2026.
-
Registry record
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
-
FDA safety communication
FDA's concerns with unapproved GLP-1 drugs used for weight loss
-
Official U.S. prescribing information
Wegovy injection and tablets, current U.S. label
-
Official U.S. prescribing information
Ozempic injection, current U.S. label
-
Official U.S. prescribing information
Rybelsus and Ozempic tablets, current U.S. label